Source-grounded facts extracted from BIO-PATH HOLDINGS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BIO-PATH HOLDINGS, INC.: Domestication to Wyoming and creation of Series S Preferred stock (effective 2026-03-05).
“On March 5, 2026, Bio-Path’s domestication to Wyoming was approved by the Secretary of State of Wyoming. The stamped paperwork and subsequently filed amendment to create a new class of Series S Preferred stock with fifty-one (51) authorized shares, each convertible into one common share and holding 1% of the diluted voting power of the company are attached.”
BIO-PATH HOLDINGS, INC. dismissed Ernst & Young LLP as its auditor.
“On August 13, 2025, the Board of Directors of Bio-Path Holdings, Inc. (the “Company”) approved the dismissal of Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm, and notified EY of the dismissal on the same date with an effective date of August 13, 2025.”
Douglas P. Morris was appointed as Chairman of the Board at BIO-PATH HOLDINGS, INC..
“On June 22, 2025, the Board appointed Douglas P. Morris to serve as Chairman of the Board.”
Aline Sherwood resigned as member of the Board at BIO-PATH HOLDINGS, INC..
“On June 21, 2025, Aline Sherwood notified the Company of her decision to resign as a member of the Board and all committees of the Board on which she served.”
Heath Cleaver resigned as member of the Board at BIO-PATH HOLDINGS, INC..
“On June 20, 2025, Heath Cleaver notified the Company of his decision to resign as a member of the Board and all committees of the Board on which he served.”
Peter H. Nielsen resigned as President, Chief Executive Officer, Chief Financial Officer, Treasurer, Principal Accounting Officer, Chairman of the Board at BIO-PATH HOLDINGS, INC..
“On June 20, 2025, Peter H. Nielsen notified the Board of Directors (the “Board”) of Bio-Path Holdings, Inc. (the “Company”) of his decision to resign as President, Chief Executive Officer, Chief Financial Officer, Treasurer, Principal Accounting Officer, Chairman of the Board, member of the Board and all committees of the Board on which he served for the Company.”
BIO-PATH HOLDINGS, INC. incurred loan of $161,000 with Quick Capital, LLC at twelve percent.
“On April 28, 2025, Bio-Path Holdings, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with Quick Capital, LLC, a Wyoming limited liability company (the “Lender”), an accredited investor, for the issuance and sale of a promissory note in the aggregate principal amount of $161,000”
BIO-PATH HOLDINGS, INC. incurred debt of $100,050 with 1800 Diagonal Lending LLC at twelve percent.
“Lending LLC, a Virginia limited liability company (the “Lender”), an accredited investor, for the issuance and sale of a promissory note in the aggregate principal amount of $100,050 (the “Note”) for a purchase price of $87,000 after deducting the original issue discount of $13,050. The Note bears a one-time interest charge of twelve percent that is applied on”
BIO-PATH HOLDINGS, INC. incurred loan of $161,000 with 1800 Diagonal Lending LLC at twelve percent.
“On March 6, 2025, Bio-Path Holdings, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with 1800 Diagonal Lending LLC, a Virginia limited liability company (the “Lender”), an accredited investor, for the issuance and sale of a promissory note in the aggregate principal amount of $161,000”
BIO-PATH HOLDINGS, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
“February 14, 2025, the Nasdaq Stock Market LLC (“Nasdaq”) notified Bio-Path Holdings, Inc. (the “Company”) that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s common stock, par value $0.001 per share (“Common Stock”), and that trading of the Company’s Common Stock will be suspended at the open of trading on February 19, 2025. As previously reported, on November 19, 2024, the Company was granted an extension until January 31, 2025 from the Panel to demonstrate compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed issuers to maintain minimum stoc”
BIO-PATH HOLDINGS, INC. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“December 12, 2024, Bio-Path Holdings, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar day”
BIO-PATH HOLDINGS, INC. reported first quarter ended March 31, 2024 results: net income $3.2 million, or $4.88 per share, EPS $4.88 per share.
“The Company reported a net loss of $3.2 million, or $4.88 per share, for the three months ended March 31, 2024, compared to a net loss of $5.3 million, or $13.25 per share, for the three months ended March 31, 2023.”
BIO-PATH HOLDINGS, INC. entered into Engagement Letter with H.C. Wainwright & Co., LLC (effective 2024-03-22).
“On March 22, 2024, the Company entered into an engagement letter (the “Engagement Letter”) with H.C. Wainwright & Co., LLC (the “Placement Agent”).”
BIO-PATH HOLDINGS, INC. entered into Purchase Agreement with certain institutional investors valued at approximately $1.2 million (effective 2024-04-18).
“On April 18, 2024, Bio-Path Holdings, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors, pursuant to which the Company agreed to sell, in a registered direct offering (the “Registered Direct Offering”), an aggregate of 375,000 shares (the “Shares”) of its common stock, par value $0.001 per share (“Common Stock”), for a purchase price per Share of $3.225 and gross proceeds of approximately $1.2 million.”
BIO-PATH HOLDINGS, INC. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at up to $2,000,000 aggregate offering price (effective 2024-04-04).
“On April 4, 2024, Bio-Path Holdings, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC, (“Wainwright”), as sales agent, pursuant to which the Company may offer and sell, from time to time, through Wainwright shares of its common stock, $0.001 par value per share.”
BIO-PATH HOLDINGS, INC. entered into Purchase Agreement with an institutional investor valued at gross proceeds of $299,250 (effective 2024-03-25).
“On March 25, 2024, Bio-Path Holdings, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor, pursuant to which the Company agreed to sell, in a registered direct offering (the “Registered Direct Offering”), an aggregate of 75,000 shares (the “Shares”) of its common stock, par value $0.001 per share (“Common Stock”), for a purchase price per Share of $3.99 and gross proceeds of $299,250.”
BIO-PATH HOLDINGS, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“March 12, 2024, Bio-Path Holdings, Inc. (the “Company”) received a deficiency letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement of at least $2,500,000 for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”). The Letter has no effect on the listing of the Company’s common stock at this time, and the Company’s common stock will continue to trade on The Nasdaq C”
BIO-PATH HOLDINGS, INC. reported the year ended December 31, 2023 results: net income $16.1 million, or $33.63 per share, EPS $33.63 per share.
“The Company reported a net loss of $16.1 million, or $33.63 per share, for the year ended December 31, 2023, compared to a net loss of $13.9 million, or $38.12 per share, for the year ended December 31, 2022.”
BIO-PATH HOLDINGS, INC.: Filed Certificate of Amendment to effect a one-for-twenty reverse stock split of Common Stock (effective 2024-02-22).
“On February 22, 2024, Bio-Path Holdings, Inc. (the “Company”) filed a Certificate of Amendment (the “Amendment”) to the Company’s Certificate of Incorporation with the Delaware Secretary of State to effect a reverse stock split of the Company’s Common Stock, par value $0.001 (the “Common Stock”) at a ratio of one-for-twenty, effective at 5:30 p.m. Eastern Time on February 22, 2024 (the “Reverse Stock Split”) .”
BIO-PATH HOLDINGS, INC. shareholders approved For the approval of an amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of the Company’s common stock, par value $0.001 per share, at a ratio of up to 1-for-50, to be determined by the Board at the 2024-01-30 meeting.
“Proposal One : For the approval of an amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of the Company’s common stock, par value $0.001 per share, at a ratio of up to 1-for-50, to be determined by the Board: Shares Voted “For” Shares Voted “Against” Shares Withheld Shares Abstained Broker Non-Votes 3,730,378.71 3,189,585.79 -- 42,153.00 --”
BIO-PATH HOLDINGS, INC.: Reduced stockholder meeting quorum threshold from majority to one-third of shares entitled to vote (effective 2023-12-07).
“On December 7, 2023, the Board of Directors (the “Board”) of Bio-Path Holdings, Inc. (the “Company”) approved Amendment No. 1 to the First Amended and Restated Bylaws of the Company for the purpose of reducing the threshold required to establish a quorum for its meetings of stockholders from a majority of shares entitled to vote at such meetings to one-third of the shares entitled to vote at such meetings.”
BIO-PATH HOLDINGS, INC. reported third quarter ended September 30, 2023 results: net income net loss of $3.2 million, or $0.32 per share, EPS $0.32 per share.
“The Company reported a net loss of $3.2 million, or $0.32 per share, for the three months ended September 30, 2023, compared to a net loss of $3.5 million, or $0.49 per share, for the three months ended September 30, 2022.”
BIO-PATH HOLDINGS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“September 13, 2023, Bio-Path Holdings, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar da”
BIO-PATH HOLDINGS, INC. reported the second quarter ended June 30, 2023 results: net income $4.2 million, or $0.53 per share.
“The Company reported a net loss of $4.2 million, or $0.53 per share, for the three months ended June 30, 2023”
BIO-PATH HOLDINGS, INC. amended Warrant Amendment Agreements (effective 2023-08-07).
“In connection with the Public Offering, the Company entered into warrant amendment letter agreements (the “Warrant Amendment Agreements”) to amend certain existing warrants to purchase up to an aggregate of 800,000 shares of the Company’s common stock that were previously issued on November 9, 2022 at an exercise price of $2.85 per share (the “Amended Warrants”), such that effective upon the closing of the Public Offering, the Amended Warrants have a reduced exercise price equal to $0.7593 per share.”
BIO-PATH HOLDINGS, INC. entered into Warrant Agency Agreement with Equiniti Trust Company, LLC (effective 2023-08-07).
“On August 7, 2023, the Company also entered into a warrant agency agreement (the “Warrant Agency Agreement”) with the Company’s transfer agent, Equiniti Trust Company, LLC, who will act as warrant agent for the Company, setting forth the terms and conditions of the Common Warrants.”
BIO-PATH HOLDINGS, INC. entered into Purchase Agreement with certain purchasers valued at gross proceeds of approximately $2.1 million (effective 2023-08-03).
“On August 3, 2023, Bio-Path Holdings, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with certain purchasers for the purchase and sale, in a registered public offering by the Company (the “Public Offering”), of an aggregate of 3,500,000 shares of its common stock, par value $0.001 per share (“Common Stock”), and accompanying common stock purchase warrants to purchase up to an aggregate of 3,500,000 shares of its Common Stock (the “Common Warrants”) at a combined public offering price of $0.60 per share of Common Stock and accompanying Common Warrant, resulting in gross proceeds of approximately $2.1 million.”
BIO-PATH HOLDINGS, INC. entered into Placement Agency Agreement with Roth Capital Partners, LLC valued at gross proceeds of approximately $2.1 million (effective 2023-08-03).
“On August 3, 2023, Bio-Path Holdings, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with certain purchasers for the purchase and sale, in a registered public offering by the Company (the “Public Offering”), of an aggregate of 3,500,000 shares of its common stock, par value $0.001 per share (“Common Stock”), and accompanying common stock purchase warrants to purchase up to an aggregate of 3,500,000 shares of its Common Stock (the “Common Warrants”) at a combined public offering price of $0.60 per share of Common Stock and accompanying Common Warrant, resulting in gross proceeds of approximately $2.1 million.”
BIO-PATH HOLDINGS, INC. reported first quarter ended March 31, 2022 results: net income a net loss of $3.4 million, or $0.47 per share.
“The Company reported a net loss of $5.3 million, or $0.66 per share, for the three months ended March 31, 2023, compared to a net loss of $3.4 million, or $0.47 per share, for the three months ended March 31, 2022.”
BIO-PATH HOLDINGS, INC. reported first quarter ended March 31, 2023 results: net income a net loss of $5.3 million, or $0.66 per share.
“The Company reported a net loss of $5.3 million, or $0.66 per share, for the three months ended March 31, 2023, compared to a net loss of $3.4 million, or $0.47 per share, for the three months ended March 31, 2022.”
BIO-PATH HOLDINGS, INC. reported the year ended December 31, 2022 results: net income a net loss of $13.9 million, or $1.91 per share.
“The Company reported a net loss of $13.9 million, or $1.91 per share, for the year ended December 31, 2022”
BIO-PATH HOLDINGS, INC. shareholders approved Ratification and approval of the appointment of Ernst & Young, LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2022 at the 2022-12-31 meeting.
“Proposal 4 : For the ratification and approval of the appointment of Ernst & Young, LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2022: Shares Voted “For” Shares Voted “Against” Shares Abstained Broker Non- Votes 3,920,967 300,923 55,107 0”
BIO-PATH HOLDINGS, INC. shareholders approved Non-binding advisory approval of the compensation of the Company’s named executive officers.
“Proposal 3 : For the non-binding advisory approval of the compensation of the Company’s named executive officers: Shares Voted “For” Shares Voted “Against” Shares Abstained Broker Non- Votes 2,076,879 237,410 25,588 1,937,120”
BIO-PATH HOLDINGS, INC. shareholders approved Approval of the 2022 Plan.
“Proposal 2 : For the approval of the 2022 Plan: Shares Voted “For” Shares Voted “Against” Shares Abstained Broker Non- Votes 1,996,284 280,998 62,595 1,937,120”
BIO-PATH HOLDINGS, INC. shareholders approved Election of Directors.
“Proposal 1 : For the election of directors of the Company, to hold office until the Company’s next annual meeting of stockholders or until their respective successors have been duly elected and qualified: Name of Nominee Shares Voted “For” Shares Voted “Against” Shares Withheld Shares Abstained Broker Non- Votes Peter H. Nielsen 2,154,714 -- 185,163 -- 1,937,120 Heath W. Cleaver 2,094,257 -- 245,620 -- 1,937,120 Paul D. Aubert 2,127,552 -- 212,325 -- 1,937,120 Aline Sherwood 2,173,586 -- 166,291 -- 1,937,120 Douglas P. Morris 2,166,978 -- 172,899 -- 1,937,120”
BIO-PATH HOLDINGS, INC. terminated At-The-Market Offering Agreement with H. C. Wainwright & Co., LLC (effective 2022-12-07).
“On December 7, 2022, the Company received written notice from Wainwright that Wainwright had elected, pursuant to Section 8(b) of the Offering Agreement, to terminate the Offering Agreement effective as of December 7, 2022.”
BIO-PATH HOLDINGS, INC. reported three months ended September 30, 2022 results: net income Net loss of $3.5 million, EPS $0.49 per share.
“The Company reported a net loss of $3.5 million, or $0.49 per share, for the three months ended September 30, 2022, compared to a net loss of $2.1 million, or $0.29 per share, for the three months ended September 30, 2021.”
BIO-PATH HOLDINGS, INC. entered into Purchase Agreements with several institutional and accredited investors valued at gross proceeds of approximately $2.0 million (effective 2022-11-06).
“On November 6, 2022, Bio-Path Holdings, Inc. (the “Company”) and several institutional and accredited investors entered into securities purchase agreements (the “Purchase Agreements”), pursuant to which the Company agreed to sell, in a registered direct offering (the “Registered Direct Offering”), an aggregate of 800,000 shares (the “Shares”) of its common stock, par value $0.001 per share (“Common Stock”), for a purchase price per Share of $2.50 and gross proceeds of approximately $2.0 million.”
Aline Sherwood was appointed as Director at BIO-PATH HOLDINGS, INC..
“On March 31, 2022, the Board appointed Aline Sherwood to the Board to fill the vacancy resulting from the resignation of Ms. Molsbergen.”
Martina Molsbergen resigned as Director at BIO-PATH HOLDINGS, INC..
“On February 14, 2022, Martina Molsbergen resigned from her position as a member of the Board of Directors (the “Board”) of Bio-Path Holdings, Inc. (the “Company”) and all committees of the Board on which she served.”
Martina Molsbergen resigned as member of the Board and all committees of the Board at BIO-PATH HOLDINGS, INC..
“On February 14, 2022, Martina Molsbergen resigned from her position as a member of the Board and all committees of the Board on which she served”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.